Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
Published version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population. SIGNIFICANCE: Rare cancers are difficult to treat; in particular, molecular pathogenesis-oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials. See rela…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Perturbation-response genes reveal signaling footprints in cancer gene expression
(2017) · doi:10.1038/s41467-017-02391-6 · Cited by 1,108
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086
Alvarez, M. J., Shen, Y., Giorgi, F. M., Lachmann, A., Ding, B. B., Ye, B. H., & Califano, A. (2016) · Nature Genetics · doi:10.1038/ng.3593 · Cited by 966
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Abkevich, V, Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith-McCune, K., Broaddus, R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 815
Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 815
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Dei Tos, A. P., Kunkler, I., Otter, R., Licitra, L., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 809
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0407-5 · Cited by 707
Popova, T., Manié, E., Rieunier, G., Caux-Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal-Zafrani, B., Bollet, M., Longy, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1470 · Cited by 665
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 661
Von Hoff, D. D., Stephenson, J. J., Rosen, P., Loesch, D. M., Borad, M. J., Anthony, S., Jameson, G., Brown, S., Cantafio, N., Richards, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5983 · Cited by 647
Haas, B. J., Dobin, A., Li, B., Stransky, N., Pochet, N., & Regev, A. (2019) · Genome biology · doi:10.1186/s13059-019-1842-9 · Cited by 646
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Rodon, J., Soria, J.-C., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 578
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Schwaederle, M., Zhao, M., Lee, J. J., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., Lazar, V., & Kurzrock, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5997 · Cited by 494
Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M.-J., Oaknin, A., Kerger, J., López-Picazo, J. M., Machiels, J.-P., Delord, J.-P., Evans, T. R. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00739 · Cited by 440
Diamond, E. L., Subbiah, V., Lockhart, A. C., Blay, J.-Y., Puzanov, I., Chau, I., Raje, N. S., Wolf, J., Erinjeri, J. P., Torrisi, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5029 · Cited by 413
Schwaederle, M., Zhao, M., Lee, J. J., Lazar, V., Leyland-Jones, B., Schilsky, R. L., Mendelsohn, J., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2129 · Cited by 348
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Pilié, P. G., Gay, C. M., Byers, L. A., O'Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 330
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1600-x · Cited by 259
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Heining, C., Horak, P., Uhrig, S., Codo, P. L., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0036 · Cited by 240
Self-citationThe Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty, K. T., Gray, R., Chen, A., Li, S., Patton, D., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz245 · Cited by 224
Alvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0138-4 · Cited by 210
Trédan, O., Wang, Q., Pissaloux, D., Cassier, P., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz080 · Cited by 189
Fontes Jardim, D. L., Schwaederle, M., Wei, C., Lee, J. J., Hong, D. S., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., Lazar, V., & Kurzrock, R. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv253 · Cited by 186
The burden of rare cancers in the United States
DeSantis, C. E., Kramer, J. L., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21400 · Cited by 186
Precision oncology based on omics data: The NCT Heidelberg experience
Horak, P., Klink, B., Heining, C., Gröschel, S., Hutter, B., Fröhlich, M., Uhrig, S., Hübschmann, D., Schlesner, M., Eils, R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30828 · Cited by 173
Self-citationGenomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Variant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 140
Self-citationA modular master regulator landscape controls cancer transcriptional identity
Paull, E. O., Aytes, A., Jones, S. J., Subramaniam, P. S., Giorgi, F. M., Douglass, E. F., Tagore, S., Chu, B., Vasciaveo, A., Zheng, S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.045 · Cited by 135
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 133
PARP inhibitors in ovarian cancer
Ledermann, J. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw094 · Cited by 132
Tamborero, D., Dienstmann, R., Rachid, M. H., Boekel, J., Baird, R. D., Braña, I., Petris, L. D., Yachnin, J., Massard, C., Opdam, F. L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0969-2 · Cited by 95
Self-citationBelin, L., Kamal, M. T., Mauborgne, C., Plancher, C., Mulot, F., Delord, J., Gonçalvès, A., Gavoille, C., Dubot, C., Isambert, N., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw666 · Cited by 93
Challenging Standard-of-Care Paradigms in the Precision Oncology Era
Subbiah, V., & Kurzrock, R. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.004 · Cited by 89
The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine
Dickson, D., Johnson, J., Bergan, R., Owens, R., Subbiah, V., & Kurzrock, R. (2020) · Cell · doi:10.1016/j.cell.2019.12.009 · Cited by 77
Targeted therapy in rare cancers—adopting the orphans
Munoz, J. L., & Kurzrock, R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.160 · Cited by 53
Community-driven development of a modified progression-free survival ratio for precision oncology
Möck, A., Heilig, C. E., Kreutzfeldt, S., Hüebschmann, D., Heining, C., Schröck, E., Brors, B., Stenzinger, A., Jäger, D., Schlenk, R. F., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000583 · Cited by 48
Self-citationDiamond, E. L., Subbiah, V., Lockhart, A. C., Blay, J., Puzanov, I. J., Chau, I., Raje, N. S., Wolf, J., Erinjeri, J. P., Torrisi, J., et al. (2018) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 48
Lier, A., Penzel, R., Heining, C., Horak, P., Fröhlich, M., Uhrig, S., Budczies, J., Kirchner, M., Volckmar, A., Hutter, B., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00171 · Cited by 44
Self-citationWeinberg, F., Griffin, R., Fröhlich, M., Heining, C., Braun, S. L., Spohr, C., Iconomou, M., Hollek, V., Röring, M., Horak, P., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1021-1 · Cited by 40
Self-citationGene expression has more power for predicting in vitro cancer cell vulnerabilities than genomics
Dempster, J. M., Krill-Burger, J. M., McFarland, J. M., Warren, A., Boehm, J. S., Vazquez, F., Hahn, W. C., Golub, T. R., & Tsherniak, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.21.959627 · Cited by 32
Cited by
van Tilburg, C. M., Pfaff, E., Pajtler, K. W., Langenberg, K. P. S., Fiesel, P., Jones, B. C., Balasubramanian, G. P., Stark, S., Johann, P. D., Blattner-Johnson, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0094 · Cited by 262
Self-citationBig data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254
“Deep convolutional neural Recent umbrella clinical trials 88–92 have focused on multi-omics profiling of the tumours of enrolled patients by generating and analysing genome-wide data — including data from DNA sequencing, gene expression profiling, and copy number profiling — to prioritize…”
BackgroundKornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0538 · Cited by 206
“The use of each patient as his or her own control allows us to evaluate the individual benefit, and it became common in precision medicine trials, such as the WINTHER and MASTER trials including heterogenous cancer entities (29, 38).”
MethodMatsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“To select efficient drugs, recent clinical trials have focused on multi-omics profiling of patients with cancer by analyzing genome-wide data, including data from DNA sequencing, gene expression profiling, and copy number profiling [66].”
BackgroundSarcoma care in the era of precision medicine
Wallander, K., Öfverholm, I., Boye, K., Tsagkozis, P., Papakonstantinou, A., Lin, Y., & Haglund de Flon, F. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13717 · Cited by 30
Metadata
- Authors
- Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., Gieldon, L., Möhrmann, L., Hanf, D., Teleanu, V., Heilig, C. E., Lipka, D. B., Allgäuer, M., Ruhnke, L., Laßmann, A., Endris, V., Neumann, O., Penzel, R., Beck, K., Richter, D., Winter, U., Wolf, S., Pfütze, K., Geörg, C., Meißburger, B., Buchhalter, I., Augustin, M., Aulitzky, W. E., Hohenberger, P., Kroiss, M., Schirmacher, P., Schlenk, R. F., Keilholz, U., Klauschen, F., Folprecht, G., Bauer, S., Siveke, J. T., Brandts, C. H., Kindler, T., Boerries, M., Illert, A. L., von Bubnoff, N., Jost, P. J., Spiekermann, K., Bitzer, M., Schulze-Osthoff, K., von Kalle, C., Klink, B., Brors, B., Stenzinger, A., Schröck, E., Hübschmann, D., Weichert, W., Glimm, H., & Fröhling, S.
- Affiliations
- German Cancer Research Center (DE)
- University Hospital Carl Gustav Carus (DE)
- 1Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
- University Hospital Heidelberg (DE)
- Nuremberg Hospital (DE)
- Robert Bosch Hospital (DE)
- Heidelberg University (DE)
- University of Würzburg (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Essen University Hospital (DE)
- Goethe University Frankfurt (DE)
- Johannes Gutenberg University Mainz (DE)
- University of Freiburg (DE)
- Medical University of Graz (AT)
- Ludwig-Maximilians-Universität München (DE)
- Universitätsklinikum Tübingen (DE)
- 49DKTK, Tübingen, Germany.
- 51Clinical Study Center, Charité – Universitätsmedizin Berlin, and Berlin Institute of Health, Berlin, Germany.
- Luxembourg Institute of Health (LU)
- Technical University of Munich (DE)
- Corresponding author
- Glimm, Hanno
- Fröhling, Stefan
- ORCID
- Horak, Peter
- Heining, Christoph
- Kreutzfeldt, Simon
- Hutter, Barbara
- Mock, Andreas
- Hüllein, Jennifer
- Fröhlich, Martina
- Uhrig, Sebastian
- Jahn, Arne
- Rump, Andreas
- Gieldon, Laura
- Möhrmann, Lino
- Hanf, Dorothea
- Heilig, Christoph E.
- Lipka, Daniel B.
- Allgäuer, Michael
- Ruhnke, Leo
- Endris, Volker
- Neumann, Olaf
- Richter, Daniela
- Buchhalter, Ivo
- Augustin, Marinela
- Aulitzky, Walter E.
- Hohenberger, Peter
- Kroiss, Matthias
- Schirmacher, Peter
- Schlenk, Richard F.
- Keilholz, Ulrich
- Klauschen, Frederick
- Folprecht, Gunnar
- Bauer, Sebastian
- Siveke, Jens Thomas
- Brandts, Christian H.
- Kindler, Thomas
- Boerries, Melanie
- Illert, Anna L.
- von Bubnoff, Nikolas
- Jost, Philipp J.
- Spiekermann, Karsten
- Bitzer, Michael
- von Kalle, Christof
- Klink, Barbara
- Brors, Benedikt
- Stenzinger, Albrecht
- Schröck, Evelin
- Hübschmann, Daniel
- Weichert, Wilko
- Glimm, Hanno
- Fröhling, Stefan
- Venue
- Cancer Discovery
- Published
- 2021-06-10
- Volume
- 11
- Issue
- 11
- Pages
- 2780-2795
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3171689169
- Cited by
- 290
- References
- 51
- Citations by year
- 2026: 49 · 2025: 57 · 2024: 54 · 2023: 67 · 2022: 50 · 2021: 12
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- German Cancer Research Center (H021)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- rare tumor, molecular profiling, molecular tumor board, targeted therapy, biomarkers, molecular stratification, clinical decision-making, progression-free survival, clinical trial access, genetic counseling, advanced cancer
- MeSH terms
- Exome Sequencing, Adult, Humans, Neoplasms, Gene Expression Profiling, Genomics, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.